Er-shun Liang

Dr. Er-shun Liang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ELEr-shun Liang
Er-shun Liang
XLXue Liu
Xue Liu
ZDZhanhui Du
Zhanhui Du
RYRuixue Yang
Ruixue Yang
YZYuxia Zhao
Yuxia Zhao
Andrographolide (Andro), a major bioactive component obtained from Andrographis paniculata Nees, has exerted wide antioxidant as well as cytoprotective properties. However, whether Andro treatment could retard the progress of diabetic cardiomyopathy (DCM) remains unknown. In this study, we evaluated the effects of Andro against diabetes‐induced myocardial dysfunction and explored the underlying mechanism in STZ‐induced diabetic mice. As a result, treatment with Andro dose dependently suppressed cardiac inflammation and oxidative stress, accompanied by decreasing cardiac apoptosis, which subsequently ameliorated cardiac fibrosis and cardiac hypertrophy. Further, Andro blocked hyperglycemia‐triggered reactive oxygen species (ROS) generation by suppressing NADPH oxidase (NOX) activation and augmenting nuclear factor erythroid 2‐related factor 2 (Nrf2) expression both in vitro and in vivo. Our results suggest that the cardioprotective effects afforded by Andro treatment involve the modulation of NOX/Nrf2‐mediated oxidative stress and NF‐κB‐mediated inflammation. The present study unravels the therapeutic potential of Andro in the treatment of DCM by attenuating oxidative stress, inflammation, and apoptosis.

18 November 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
XLXue Liu
Xue Liu
YLYan Liu
Yan Liu
RYRui-Xue Yang
Rui-Xue Yang
XDXiangjiu Ding
Xiangjiu Ding
ELEr-shun Liang
Er-shun Liang
Rationale: Genetic studies have proved the involvement of Tuberous sclerosis complex subunit 2 (Tsc2) in aortic aneurysm. However, the exact role of macrophage Tsc2 in the vascular system remains unclear. Here, we examined the potential function of macrophage Tsc2 in the development of aortic remodeling and aortic aneurysms. Methods and results: Conditional gene knockout strategy combined with histology and whole-transcriptomic analysis showed that Tsc2 deficiency in macrophages aggravated the progression of aortic aneurysms along with an upregulation of proinflammatory cytokines and matrix metallopeptidase-9 in the angiotensin II-induced mouse model. G protein-coupled receptor 68 (Gpr68), a proton-sensing receptor for detecting the extracellular acidic pH, was identified as the most up-regulated gene in Tsc2 deficient macrophages compared with control macrophages. Additionally, Tsc2 deficient macrophages displayed higher glycolysis and glycolytic inhibitor 2-deoxy-D-glucose treatment partially attenuated the level of Gpr68. We further demonstrated an Tsc2-Gpr68-CREB network in macrophages that regulates the inflammatory response, proteolytic degradation and vascular homeostasis. Gpr68 inhibition largely abrogated the progression of aortic aneurysms caused by Tsc2 deficiency in macrophages. Conclusions: The findings reveal that Tsc2 deficiency in macrophages contributes to aortic aneurysm formation, at least in part, by upregulating Gpr68 expression, which subsequently drives proinflammatory processes and matrix metallopeptidase activation. The data also provide a novel therapeutic strategy to limit the progression of the aneurysm resulting from Tsc2 mutations.

6 February 2020 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PLPeng Li
Peng Li
YWYing Wang
Ying Wang
XLXue Liu
Xue Liu
BLBin Liu
Bin Liu
ZWZhao-Yang Wang
Zhao-Yang Wang
MZMingxiang Zhang
Mingxiang Zhang
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

13 August 2024 in International Journal of Cardiology
Verified
Journal Article
Closed access
ELEr-shun Liang
Er-shun Liang
XLXue Liu
Xue Liu

15 June 2022 in Oncotarget
Verified
Journal Article
Open access
XLXue Liu
Xue Liu
XSXiuhui Song
Xiuhui Song
JLJianjun Lu
Jianjun Lu
XCXueying Chen
Xueying Chen
ELEr-shun Liang
Er-shun Liang
YZYuxia Zhao
Yuxia Zhao
[This corrects the article DOI: 10.18632/oncotarget.11225.].